Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) calcium gluconate passed the consistency of quality and efficacy evaluation for generic drugs in China.
The drug is indicated for treating hand-foot weakness caused by calcium deficiency, acute hypocalcemia, allergic diseases, relief from fluorosis, and cardiac resuscitation, among other conditions.
The pharmaceuticals and chemical products company's shares closed over 3% higher on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments